Free Trial
OTCMKTS:CLPBF

Coloplast A/S (CLPBF) Stock Price, News & Analysis

Coloplast A/S logo
$108.10 -0.45 (-0.41%)
As of 02/21/2025 01:59 PM Eastern

About Coloplast A/S Stock (OTCMKTS:CLPBF)

Key Stats

Today's Range
$108.10
$108.55
50-Day Range
$105.50
$113.09
52-Week Range
$104.75
$143.15
Volume
240 shs
Average Volume
213 shs
Market Capitalization
N/A
P/E Ratio
9.47
Dividend Yield
6.94%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.

Coloplast A/S Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
7th Percentile Overall Score

CLPBF MarketRank™: 

Coloplast A/S scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Coloplast A/S.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Coloplast A/S is 9.47, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 23.66.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Coloplast A/S is 9.47, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.79.

  • Read more about Coloplast A/S's valuation and earnings.
  • Percentage of Shares Shorted

  • Short Interest Ratio / Days to Cover

    Coloplast A/S has a short interest ratio ("days to cover") of 7973, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Coloplast A/S has recently decreased by 0.77%, indicating that investor sentiment is improving.
  • Dividend Yield

    Coloplast A/S pays a meaningful dividend of 1.54%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Coloplast A/S does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Coloplast A/S is 65.69%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Read more about Coloplast A/S's dividend.
  • Percentage of Shares Shorted

  • Short Interest Ratio / Days to Cover

    Coloplast A/S has a short interest ratio ("days to cover") of 7973, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Coloplast A/S has recently decreased by 0.77%, indicating that investor sentiment is improving.
  • MarketBeat Follows

    1 people have added Coloplast A/S to their MarketBeat watchlist in the last 30 days.
Receive CLPBF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Coloplast A/S and its competitors with MarketBeat's FREE daily newsletter.

CLPBF Stock News Headlines

Coloplast A/S (0QBO) Gets a Hold from Kepler Capital
Nvidia’s Next Big Move Comes on Feb. 26
Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of companies partnering with Nvidia on its latest AI Superproject … Companies we refer to as Nvidia's "Silent Partners" … And they could benefit greatly as well on Feb. 26.
Coloplast stock rises on solid Q1 results
Coloplast A/S - Interim Financial Report, Q1 2024/25
Coloplast A/s (OTC: CLPB.Y)
See More Headlines

CLPBF Stock Analysis - Frequently Asked Questions

Coloplast A/S's stock was trading at $108.2810 on January 1st, 2025. Since then, CLPBF stock has decreased by 0.2% and is now trading at $108.10.
View the best growth stocks for 2025 here
.

Shares of CLPBF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Today
2/22/2025
Next Earnings (Estimated)
5/06/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Medical Instruments & Supplies
Sub-Industry
N/A
Current Symbol
OTCMKTS:CLPBF
Fax
N/A
Employees
15,930
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (OTCMKTS:CLPBF) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners